Compounded Semaglutide After the Shortage: Still Safe and Legal?

How Compounded Semaglutide Became So Common

For most of 2022 through 2024, brand-name GLP-1s were genuinely hard to get. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) sat on the FDA's official drug shortage list, and demand far outran supply. Federal law includes a deliberate release valve for exactly that situation: when an approved drug is in shortage, compounding pharmacies are allowed to make copies of it, something they normally cannot do.

That single exception is what built the compounded-GLP-1 industry. Telehealth companies paired with pharmacies to ship semaglutide, frequently for a few hundred dollars a month or less, at a time when a Wegovy pen carried a list price well over a thousand dollars. For many people, compounded semaglutide was not a shortcut. It was the only version they could afford or find.

The catch was always that this lane depended entirely on the shortage continuing. Once the shortage ended, the legal basis for mass-produced copies would end with it. In 2025, that is exactly what happened.

What "Off the Shortage List" Actually Means: 503A vs 503B

To understand what changed, it helps to know that not all compounders are the same. Federal law recognizes two categories, and they landed in very different places after the shortage ended.

503A pharmacies are traditional state-licensed pharmacies. They compound a medication for a specific patient in response to a prescription, one order at a time, and they are overseen mainly by state boards of pharmacy.

503B outsourcing facilities make compounded drugs in larger batches, often without a prescription tied to a named patient, and sell them to clinics and providers. They register with the FDA, are inspected by the FDA, and must follow stricter manufacturing standards. Most of the industrial-scale compounded semaglutide flowed through this 503B channel.

Both categories are barred from routinely making a drug that is "essentially a copy" of an approved product. The shortage exception was the workaround. When the FDA removed semaglutide from the shortage list, it pulled that workaround out from under both categories, though on slightly different timelines.

The Timeline: When Each Deadline Landed

The FDA moved through tirzepatide first, then semaglutide.

Tirzepatide. The FDA determined the tirzepatide shortage resolved in December 2024. It then gave compounders a wind-down window: 503A pharmacies had until February 18, 2025, and 503B facilities until March 19, 2025, before the agency would begin enforcing against copies.

Semaglutide. On February 21, 2025, the FDA declared the semaglutide shortage resolved. It set later deadlines than tirzepatide to avoid abruptly cutting off patients: 503A pharmacies had until April 22, 2025, and 503B facilities until May 22, 2025. After those dates, the shortage-based permission to make semaglutide copies was gone.

The FDA framed these staggered dates as a way to prevent an overnight disruption in treatment while still closing the door on large-scale copying.

The Lawsuits: Why the Courts Sided With the FDA

Compounding trade groups did not accept the deadlines quietly. The Outsourcing Facilities Association (OFA), which represents 503B facilities, sued the FDA over both determinations, arguing the agency acted too abruptly and understated the risk of localized supply gaps.

The courts were not persuaded. In the tirzepatide case, a federal district court in Texas denied the association's request for a preliminary injunction on March 5, 2025. In the semaglutide case, the court likewise denied a preliminary injunction on April 24, 2025. In practical terms, the enforcement deadlines held, and compounders could no longer rely on the shortage exception to justify copying either drug.

What Is Still Legal in 2026: The Narrow 503A Lane

Here is the nuance that gets lost in headlines announcing a "ban." Compounding semaglutide is not flatly illegal. What ended was the ability to make copies at scale. A patient-specific route still exists, and in April 2026 the FDA spelled out how narrow it is.

Under section 503A, a pharmacy may compound a drug for an identified individual patient based on a valid prescription. It may not, however, regularly make products that are "essentially a copy" of an approved drug. In an April 1, 2026 policy statement, the FDA said for the first time exactly what it counts as a copy: a compounded GLP-1 is essentially a copy when it has the same active ingredient as the approved product at the same, similar, or easily substitutable strength, and can be given by the same route.

The only way out of the "copy" label is a genuine, documented clinical difference for a specific patient. Crucially, the FDA said this cannot be boilerplate applied to everyone. The prescriber has to determine and document, for that individual, that the compounded formulation produces a significant difference the approved drug cannot.

The agency also gave a concrete example that matters for the telehealth market. Semaglutide combined with vitamin B12, the pairing many online programs sold, is still considered essentially a copy when it is injected like the brand and the ingredient strengths are within about 10 percent of the commercial products. In other words, adding B12 does not by itself make a legal compounded product, because a patient could simply take approved semaglutide and B12 separately.

The FDA added one limited cushion: it does not currently intend to act against a 503A pharmacy that fills four or fewer prescriptions of an essentially-a-copy product in a calendar month. That is a narrow enforcement allowance, not a green light for a business model.

The Door Is Closing Further: The 503B Bulks Proposal

The 503B channel has its own gate. An outsourcing facility can generally only compound from a bulk drug substance if that substance is on the FDA's "503B bulks list," meaning the agency has found a clinical need for it, or if the drug is on the shortage list. Semaglutide and tirzepatide are on neither.

On April 30, 2026, the FDA went a step further and formally proposed to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list altogether, concluding there is no clinical need for outsourcing facilities to make them from bulk. The agency opened a public comment period running through the end of June 2026 before issuing a final decision. If finalized, it would durably close the bulk-compounding route for these drugs rather than leaving it merely unavailable for now.

Safety: What the FDA Has Actually Flagged

Legality is only half the picture. The other half is that compounded drugs are not FDA approved, which means no one verifies their safety, strength, or quality before they reach you. The FDA has raised specific, documented concerns.

• Adverse-event reports. As of November 30, 2024, the FDA had received 392 reports of adverse events involving compounded semaglutide and 215 involving compounded tirzepatide. Reports do not prove the product caused the harm, but the volume is not trivial.
• Dosing errors. In a July 2024 alert, the FDA warned that people unfamiliar with drawing medication from a vial, and confused between milligrams, milliliters, and "units," had given themselves 5 to 20 times the intended dose. Some required hospitalization. Approved pens are pre-measured; many compounded products are not.
• Salt forms. Some compounded products used semaglutide salt forms, such as semaglutide sodium or semaglutide acetate, that differ from the active ingredient in approved medicines and have not been evaluated for safety or effectiveness. The FDA has said it is not aware of a basis for compounding with these salts.
• Unstudied add-ins. Extra ingredients marketed alongside semaglutide, such as B12, B6, L-carnitine, or NAD, have not been established as safe or effective in combination with the drug.

None of this means every compounded vial is unsafe. Many patients used compounded semaglutide without incident. It means the guardrails that come standard with an approved product, verified potency, tested sterility, pre-measured dosing, are not guaranteed, and the responsibility to vet the source shifts onto you and your prescriber.

What This Does to Cost

The compounded boom was, above all, about price. With large-scale 503B production restricted, the cheapest supply is the most exposed. Expect the low end of the compounded market to shrink, and expect surviving patient-specific compounding to cost more than the mass-produced versions did, because it is made one prescription at a time.

That does not automatically leave patients stranded at brand list prices. The access landscape has shifted in 2026 through direct-to-consumer cash programs from the manufacturers and new coverage pathways. If a compounded prescription ends, the practical question is not "brand list price or nothing," but which of the now-broader legitimate options fits your situation. Our 2026 cost guide walks through every path and what each actually costs.

If You Take Compounded Semaglutide Right Now

If you are currently on compounded semaglutide, this is a moment to plan, not to panic.

• Do not stop abruptly on your own. Suddenly discontinuing can bring back appetite and often weight. Any change should be a decision made with your prescriber.
• Ask what is actually in your product — the exact active ingredient, the salt form if any, the strength, and whether it is compounded for you specifically or was a bulk batch.
• Ask whether your source is still operating within the rules, given the deadlines and the 503A copy limits described above.
• Map your fallback before your supply is interrupted. Review whether a branded product, a manufacturer cash program, or insurance coverage is now reachable. Our compounded GLP-1 overview and provider reviews can help you compare.

FAQ: Common Questions

Is compounded semaglutide still legal in 2026?

It depends on how it is made. Large-scale, mass-produced compounded semaglutide is no longer permitted now that the FDA shortage has ended. But a state-licensed 503A pharmacy can still compound semaglutide for an individual patient with a valid prescription when the prescriber documents a clinically meaningful, patient-specific reason that the compounded version is not simply a copy of the approved drug.

When did the FDA take semaglutide off the shortage list?

The FDA declared the semaglutide shortage resolved on February 21, 2025. It gave 503A pharmacies until April 22, 2025 and 503B outsourcing facilities until May 22, 2025 to stop compounding copies. Tirzepatide came off the list earlier, with 503A and 503B deadlines of February 18 and March 19, 2025.

What is the difference between a 503A pharmacy and a 503B outsourcing facility?

A 503A pharmacy compounds patient-specific prescriptions one at a time and is regulated mainly by state boards of pharmacy. A 503B outsourcing facility makes compounded drugs in bulk, often without a prescription for a named patient, and registers with and is inspected by the FDA. After the shortage ended, 503B facilities lost the main legal route to make semaglutide and tirzepatide in bulk.

Is compounded semaglutide safe?

Compounded drugs are not FDA approved, so their safety, quality, and dosing are not verified before sale. The FDA has received hundreds of adverse-event reports, has warned about dosing errors of 5 to 20 times the intended amount from self-injection, and has flagged unapproved salt forms of semaglutide. That does not mean every compounded product is dangerous, but it does mean the safety net is thinner than with an approved pen or vial.

What should I do if I am currently taking compounded semaglutide?

Do not stop suddenly on your own. Talk with your prescriber about whether your current source is still operating legally, whether a branded product or an authorized lower-cost option is now within reach, and what your transition plan looks like if your compounded supply is discontinued. Ask exactly what is in your formulation and at what strength.

The Bottom Line

The compounded-semaglutide era was built on a temporary shortage, and that shortage is over. Mass-produced copies have lost their legal footing, the courts have backed the FDA, and a 2026 proposal aims to close the bulk route for good. What survives is a narrow, patient-specific lane that most telehealth-style programs do not fit.

If compounded semaglutide has been your route, the smart move is to understand exactly what you are taking, confirm your source is legitimate, and build a plan with your prescriber for what comes next, ideally before any interruption forces the decision for you.

Related Articles

• Compounded GLP-1 Medications: The Complete Guide
• The Real Monthly Cost of GLP-1s in 2026 (Every Path Compared)
• Compounded vs Brand-Name Semaglutide: What Is the Difference?
• GLP-1 Provider Reviews: Full Comparison

References

• U.S. Food and Drug Administration. "FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize." Drug Alerts and Statements (statement issued April 1, 2026). fda.gov — 503A copy standard, four-prescription enforcement note, semaglutide-plus-B12 example, and 503B bulks status.
• U.S. Food and Drug Administration. "FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List." Press announcement, April 30, 2026. fda.gov — proposed bulks-list exclusion and comment period.
• U.S. Food and Drug Administration. "Declaratory Order: Resolution of Shortages of Semaglutide Injection." February 2025. fda.gov — resolution finding and 503A/503B wind-down dates.
• U.S. Food and Drug Administration. "FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products." July 2024. fda.gov — 5-to-20-times dosing errors.
• U.S. Food and Drug Administration. "FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss." fda.gov — adverse-event counts (as of Nov 30, 2024), salt forms, and unstudied additives.
• Foley & Lardner LLP. "FDA Clarifies Policies for Pharmacy Compounders of GLP-1 Products." Health Care Law Today, April 14, 2026. foley.com — analysis of the April 1, 2026 FDA statement.
• McDermott Will & Emery. "GLP-1 Update: Court Backs FDA in Tirzepatide Compounding Case." mcdermottlaw.com — Outsourcing Facilities Association v. FDA preliminary-injunction rulings.
• National Community Pharmacists Association. "FDA ends compounding discretion for tirzepatide, maintains discretion for semaglutide." March 13, 2025. ncpa.org — tirzepatide 503A/503B deadlines.